Beyond Air

Beyond Air's mission is to disrupt the standard of care for inhaled nitric oxide therapy with its proprietary LungFit platform, which generates NO on-demand from ambient air. The company has achieved FDA approval for its LungFit PH system for neonatal hypoxic respiratory failure and is advancing a pipeline exploring high-concentration NO for viral pneumonia, chronic lung infections, and even oncology. Its strategy hinges on expanding the therapeutic applications of NO while leveraging a cost-effective, 'green' delivery technology to capture market share across hospital and home settings.

The LungFit platform uses patented Ionizer™ technology to generate unlimited, on-demand inhaled nitric oxide (iNO) from ambient air, eliminating the need for high-pressure gas cylinders.

Beyond Air competes directly with Mallinckrodt's INOmax in the neonatal iNO market, where it must displace an entrenched standard. In its novel high-concentration programs, it faces competition from standard antimicrobials and supportive care, while its oncology program is a first-in-class approach with no direct gaseous NO competitors.